Werbung
Vion konnte anfang des Jahres durch eine Kapitalerhöhung, seine Cashposition um 30. Mio USD auf 68 Mio. USD ausbauen.
Zudem weisst das Unternehmen mit geringen Verlusten,
optimistische Zahlen für das 2. Quartal 2005 aus.
NEW HAVEN, CT, August 5, 2005 – VION PHARMACEUTICALS, INC. (NASDAQ
SMALLCAP: VION) today announced results for the second quarter and six-month period
ended June 30, 2005.
The Company reported a net loss of $5.1 million, or $0.08 per share, for the three-month period ended June 30, 2005, compared to a net loss of $3.7 million, or $0.07 per share, for the same period in 2004. Weighted-average common shares outstanding for the three months ended June 30, 2005 and 2004 were 65.9 million and 55.3 million, respectively. Total operating expenses were $5.6 million and $3.9 million for the three months ended June 30, 2005 and 2004, respectively. The increase in operating expenses was primarily due to costs associated with the Company’s preclinical product development and higher clinical trial expenses, mainly as a result of costs associated with the Company’s Phase III clinical trial of CLORETAZINE (VNP40101M) initiated in March 2005.
For the six-month period ended June 30, 2005, the net loss was $9.7 million, or $0.15 per share, compared to a net loss of $6.9 million, or $0.13 per share, for the same period in 2004. Weighted-average common shares outstanding for the six months ended June 30, 2005 and 2004 were 64.3 million and 51.3 million, respectively. Total operating expenses were $10.5 million and $7.3 million for the six months ended June 30, 2005 and 2004, respectively. The increase in operating expenses was primarily due to higher clinical trial expenses, mainly as a result of costs associated with the Company’s Phase III clinical trial of CLORETAZINE(VNP40101M) initiated in March 2005, and costs associated with the Company’s preclinical product development.
The Company reported ending the quarter with $62.3 million in cash and cash equivalents.
Vion Pharmaceuticals, Inc. is developing anticancer agents. Vion has two agents in clinical trials: CLORETAZINE™ (VNP40101M), a unique sulfonylhydrazine alkylating agent, is being valuated in five clinical trials, including a Phase III trial in combination with Ara-C in relapsed acute myelogenous leukemia, and Triapine®, a potent inhibitor of a key step in DNA synthesis, is being evaluated in combination with gemcitabine in a Phase II trial in pancreatic cancer and additional clinical trials sponsored by the National Cancer Institute. In preclinical studies, Vion is evaluating KS119W,
a hypoxia-selective compound from the sulfonylhydrazine class,
and heterocyclic hydrazones. The Company is also seeking development partners for TAPET®, its modified Salmonella vector used to deliver anticancer agents directly to umors.
Zudem weisst das Unternehmen mit geringen Verlusten,
optimistische Zahlen für das 2. Quartal 2005 aus.
NEW HAVEN, CT, August 5, 2005 – VION PHARMACEUTICALS, INC. (NASDAQ
SMALLCAP: VION) today announced results for the second quarter and six-month period
ended June 30, 2005.
The Company reported a net loss of $5.1 million, or $0.08 per share, for the three-month period ended June 30, 2005, compared to a net loss of $3.7 million, or $0.07 per share, for the same period in 2004. Weighted-average common shares outstanding for the three months ended June 30, 2005 and 2004 were 65.9 million and 55.3 million, respectively. Total operating expenses were $5.6 million and $3.9 million for the three months ended June 30, 2005 and 2004, respectively. The increase in operating expenses was primarily due to costs associated with the Company’s preclinical product development and higher clinical trial expenses, mainly as a result of costs associated with the Company’s Phase III clinical trial of CLORETAZINE (VNP40101M) initiated in March 2005.
For the six-month period ended June 30, 2005, the net loss was $9.7 million, or $0.15 per share, compared to a net loss of $6.9 million, or $0.13 per share, for the same period in 2004. Weighted-average common shares outstanding for the six months ended June 30, 2005 and 2004 were 64.3 million and 51.3 million, respectively. Total operating expenses were $10.5 million and $7.3 million for the six months ended June 30, 2005 and 2004, respectively. The increase in operating expenses was primarily due to higher clinical trial expenses, mainly as a result of costs associated with the Company’s Phase III clinical trial of CLORETAZINE(VNP40101M) initiated in March 2005, and costs associated with the Company’s preclinical product development.
The Company reported ending the quarter with $62.3 million in cash and cash equivalents.
Vion Pharmaceuticals, Inc. is developing anticancer agents. Vion has two agents in clinical trials: CLORETAZINE™ (VNP40101M), a unique sulfonylhydrazine alkylating agent, is being valuated in five clinical trials, including a Phase III trial in combination with Ara-C in relapsed acute myelogenous leukemia, and Triapine®, a potent inhibitor of a key step in DNA synthesis, is being evaluated in combination with gemcitabine in a Phase II trial in pancreatic cancer and additional clinical trials sponsored by the National Cancer Institute. In preclinical studies, Vion is evaluating KS119W,
a hypoxia-selective compound from the sulfonylhydrazine class,
and heterocyclic hydrazones. The Company is also seeking development partners for TAPET®, its modified Salmonella vector used to deliver anticancer agents directly to umors.
